SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
HealthEquity, Inc. (HQY) trades at a trailing P/E of 33.4, forward P/E of 17.6. Trailing earnings yield is 3.00%, forward earnings yield 5.68%. PEG 0.27 (Peter Lynch undervalued ≤1.0). Graham Number is $37.09.
Criteria proven by this page:
- VALUE (49/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 17.6 (down from trailing 33.4) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.27 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 3.00% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 5.68% as earnings recover.
- Analyst consensus target $107.67 (+32.3% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 77/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
49/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HQY
Valuation Multiples
P/E (TTM)33.4
Forward P/E17.6
PEG Ratio0.27
Forward PEG0.20
P/B Ratio3.41
P/S Ratio5.42
EV/EBITDA24.2
Per Share Data
EPS (TTM)$2.50
Forward EPS (Est.)$4.62
Book Value / Share$24.46
Revenue / Share$15.25
FCF / Share$5.10
Yields & Fair Value
Earnings Yield3.00%
Forward Earnings Yield5.68%
Dividend Yield0.00%
Graham Number$37.09
SharesGrow IV$932.43 (+1046.1%)
Analyst Target$107.67 (+32.3%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2017 |
102.8 |
1.86 |
10.35 |
15.20 |
- |
| 2018 |
64.5 |
0.85 |
8.82 |
13.30 |
- |
| 2019 |
52.2 |
1.01 |
8.08 |
13.42 |
- |
| 2020 |
111.6 |
-2.20 |
4.30 |
8.32 |
- |
| 2021 |
704.6 |
-8.85 |
4.51 |
8.49 |
- |
| 2022 |
-100.3 |
0.19 |
2.40 |
5.87 |
- |
| 2023 |
-196.5 |
4.73 |
2.71 |
5.96 |
- |
| 2024 |
116.1 |
-0.37 |
3.18 |
6.47 |
- |
| 2025 |
99.2 |
1.40 |
4.54 |
7.99 |
- |
| 2026 |
34.3 |
0.27 |
3.50 |
5.62 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$0.44 |
$178.37M |
$26.38M |
14.8% |
| 2018 |
$0.77 |
$229.53M |
$47.36M |
20.6% |
| 2019 |
$1.17 |
$287.24M |
$73.9M |
25.7% |
| 2020 |
$0.58 |
$531.99M |
$39.66M |
7.5% |
| 2021 |
$0.12 |
$733.57M |
$8.83M |
1.2% |
| 2022 |
$-0.53 |
$756.56M |
$-44.29M |
-5.9% |
| 2023 |
$-0.31 |
$861.75M |
$-26.14M |
-3% |
| 2024 |
$0.64 |
$999.59M |
$55.71M |
5.6% |
| 2025 |
$1.09 |
$1.2B |
$96.7M |
8.1% |
| 2026 |
$2.46 |
$1.31B |
$215.2M |
16.4% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$3.96 |
$3.93 – $3.98 |
$1.31B |
$1.3B – $1.32B |
11 |
| 2027 |
$4.62 |
$4.57 – $4.66 |
$1.41B |
$1.4B – $1.42B |
11 |
| 2028 |
$5.34 |
$5.17 – $5.47 |
$1.53B |
$1.51B – $1.55B |
10 |
| 2029 |
$6.20 |
$6.10 – $6.31 |
$1.62B |
$1.6B – $1.64B |
4 |
